Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best short squeeze stocks to invest in. On May 22, Cantor Fitzgerald restated its Overweight rating for Summit Therapeutics Inc. (NASDAQ:SMMT). The firm addressed concerns about the HARMONi-3 trial, which is evaluating ivonescimab in first-line squamous non-small cell lung cancer.

The trial failed to meet an interim progression-free survival threshold, increasing investor doubts regarding its efficacy in comparison to data from HARMONi-6, a China-exclusive trial.

Cantor Fitzgerald reported that medical professionals were less deterred by the interim progression-free survival shortfall. The expert opinion was influenced by the firm’s low alpha spend and the fact that the analysis was performed very early.

Meanwhile, H.C. Wainwright downgraded Summit Therapeutics Inc. (NASDAQ:SMMT) to Neutral from Buy, noting competition from Merck’s sacituzumab tirumotecan results. The firm stated that sacituzumab tirumotecan, coupled with pembrolizumab, had an immature overall survival hazard ratio of 0.55, which might place strain on Summit’s ivonescimab if the trend continues with prolonged follow-up.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical firm. The company’s main product, Ridinilazole, is an orally administered small-molecule antibiotic now in Phase III clinical trials to treat CDI.

While we acknowledge the risk and potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SMMT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1